WallStreetZenWallStreetZen

NASDAQ: NPCE
Neuropace Inc Stock Ownership - Who owns Neuropace?

Insider buying vs selling

Have Neuropace Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Kck Ltd10% Owner2024-10-023,843$6.87
$26.40kSell
Kck Ltd10% Owner2024-10-014,882$6.77
$33.05kSell
Kck Ltd10% Owner2024-09-304,749$6.73
$31.96kSell
Kck Ltd10% Owner2024-09-275,059$6.63
$33.54kSell
Kck Ltd10% Owner2024-09-265,821$6.62
$38.54kSell
Kck Ltd10% Owner2024-09-255,858$6.60
$38.66kSell
Kck Ltd10% Owner2024-09-23282$7.54
$2.13kSell
Kck Ltd10% Owner2024-09-20765$7.50
$5.74kSell
Kck Ltd10% Owner2024-09-131,993$7.59
$15.13kSell
Kck Ltd10% Owner2024-09-0611$7.50
$82.50Sell

1 of 5

NPCE insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when NPCE insiders and whales buy or sell their stock.

NPCE Shareholders

What type of owners hold Neuropace Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Greg Shaw Garfield19.36%5,653,237$37.37MInsider
Kck Ltd19.02%5,554,089$36.71MInsider
URI Geiger15.18%4,432,948$29.30MInsider
Accelmed Partners Ii LP15.18%4,432,948$29.30MInsider
Evan Norton13.85%4,042,657$26.72MInsider
Orbimed Advisors LLC12.47%3,641,335$24.07MInsider
Orbimed Advisors LLC11.67%3,406,335$22.52MInstitution
Morgan Stanley8.46%2,471,142$16.33MInstitution
Soleus Capital Management LP8.33%2,433,168$16.08MInstitution
Kent Lake Capital LLC3.92%1,144,254$7.56MInstitution

1 of 3

NPCE vs Medical Device Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
NPCE32.79%67.21%Net SellingNet Selling
PROF38.84%0.00%
NVRO72.35%27.65%Net SellingNet Selling
SENS10.98%39.17%Net SellingNet Buying
SMLR36.03%63.97%Net BuyingNet Buying

Neuropace Stock Ownership FAQ

Who owns Neuropace?

Neuropace (NASDAQ: NPCE) is owned by 49.42% institutional shareholders, 101.32% Neuropace insiders, and 0.00% retail investors. Greg Shaw Garfield is the largest individual Neuropace shareholder, owning 5.65M shares representing 19.36% of the company. Greg Shaw Garfield's Neuropace shares are currently valued at $36.52M.

If you're new to stock investing, here's how to buy Neuropace stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.